News and Press Releases
Press releases
Theralase Releases Quarterly Newsletter
Toronto, Ontario – Jan 07, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stag...
0Theralase Releases Third Quarter 2019 Financial Results and Company Update
TORONTO, ON/ November 29, 2019 / Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmac...
0Theralase Researchers Receive Recognition for Recent Scientific Publications
Toronto, Ontario – November 27, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0Theralase Announces Leadership Transition
Toronto, Ontario – October 31, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), ), a clinic...
0Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds
Toronto, Ontario – October 22, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical ...
0London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Toronto, Ontario – October 07, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), ), a clinic...
0Theralase Files Investigational New Drug Application with the FDA
Toronto, Ontario – October 01, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical ...
0Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
Toronto, Ontario – September 30, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
0Theralase Grants Stock Options
TORONTO, ON / September 13, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage ...
0Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / September 4, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a cli...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.